Kingsview Wealth Management’s abrdn Life Sciences Investors HQL Stock Holding History
Bought
Maintained
Sold
Other funds holding HQL
SCM
PCM
NIM
FHA
RCM
Kingsview Wealth Management's HQL Position: Q1 2026 in Review
Kingsview Wealth Management reduced its abrdn Life Sciences Investors (HQL) stake by 0.44% in Q1 2026, selling an estimated $2.64K and leaving 35,716 shares worth $581K. The position accounts for 0.01% of the portfolio, ranked #848.
Kingsview Wealth Management first reported a position in HQL in Q1 2021 and has held it in 21 quarters since. The position peaked at $628K in Q4 2021. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.
- Kingsview Wealth Management held 35,716 shares of abrdn Life Sciences Investors worth $581K as of Q1 2026.
- Kingsview Wealth Management sold 158 abrdn Life Sciences Investors shares in Q1 2026, an estimated $2.64K.
- abrdn Life Sciences Investors made up 0.01% of Kingsview Wealth Management's portfolio in Q1 2026, its #848 holding.
- Kingsview Wealth Management first reported a position in abrdn Life Sciences Investors in Q1 2021 and has held it in 21 quarters since.
- Kingsview Wealth Management's abrdn Life Sciences Investors position peaked at $628K in Q4 2021.
- 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.
Based on Kingsview Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.